Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL7713759 | 0.96 | TDP1 (0.36) | TDP1DGAT1CA1CA2CA7 | |
| Silver SCHEMBL21834857 | 0.96 | TDP1 (0.36) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL1374814 | 0.80 | DGAT1 (0.52) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL14276786 | 0.79 | TDP1 (0.39) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL2541061 | 0.78 | DGAT1 (0.45) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL2543922 | 0.78 | DGAT1 (0.45) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL76832 | 0.77 | KDM4C (0.41) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL19154278 | 0.76 | TDP1 (0.37) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL21952155 | 0.76 | TDP1 (0.37) | TDP1DGAT1CA1CA2CA7 | |
| SCHEMBL9304597 | 0.76 | APLNR (0.38) | TDP1DGAT1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008062-B1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-04-05 | — | — | EP | disclosed |
| US-9586958-B2 | Prodrug derivatives of substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20160207915-A1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| EP-3008062-A2 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014198647-A2 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207915-A1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | TK1, PNKP, MPST | TDP1 42/4885DGAT1 4181/4885CA1 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.